Given the clinic application of HDAC inhibitors (HDACi) in cancer treatment [73-80], and the promising result of HDACi in preclinical and clinical studies of stroke [81-86], the reuse of HDACi in stroke clinic should be expedited. Here, HDAC9 is linked to stroke disorder.